Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.73 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29610430 | 0.96 | OPRM1 (0.77) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL22959877 | 0.96 | OPRM1 (0.77) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3477727 | 0.94 | OPRM1 (0.73) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3477477 | 0.92 | OPRM1 (0.71) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL7770909 | 0.92 | OPRM1 (0.71) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL7775794 | 0.92 | OPRM1 (0.71) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL2322859 | 0.92 | OPRM1 (0.78) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL22959880 | 0.89 | OPRM1 (0.66) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3477203 | 0.88 | OPRM1 (0.70) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13250907 | 0.88 | OPRM1 (0.84) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222296-B2 | Conjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-07-17 | — | — | US | disclosed |
| US-20090304584-A1 | CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AND THEIR USE IN TREATING CNS DISORDERS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304584-A1 | CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AND THEIR USE IN TREATING CNS DISORDERS | GABBR1, GABBR2, GABRG3 | OPRM1 149/4885OPRK1 94/4885OPRD1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.